• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

动物中碳青霉烯类耐药肠杆菌科的传播意识作为一种健康。

Awareness on the spread of carbapenem-resistant Enterobacterales in animals as One Health.

机构信息

Department of Infectious Diseases, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea.

出版信息

J Vet Sci. 2024 Nov;25(6):e83. doi: 10.4142/jvs.24251.

DOI:10.4142/jvs.24251
PMID:39608777
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11611490/
Abstract

One Health is a multisectoral cooperative and collaborative approach aimed at achieving integrated health by recognizing the interconnectedness of people, animals, plants, and the environment. In the modern world, the One Health approach is considered an essential perspective for overcoming various emerging diseases, including antimicrobial resistance (AMR). One of the top priority AMR infections is caused by carbapenem-resistant Enterobacterales (CRE), which are bacterial strains not susceptible to carbapenems, the last-resort antibiotics for clinical Gram-negative bacterial infections. Although carbapenems are not allowed to use in animals in the global community, various types of CRE are being reported among animals, including the carbapenemase-producing Enterobacterales (CPE). Therefore, since the dissemination and clinical infection of CPE represent a shared health threat, measures to raise awareness of this issue should be considered from the perspective of the One Health approach.

摘要

One Health 是一种多部门合作和协作的方法,旨在通过认识到人类、动物、植物和环境的相互联系来实现综合健康。在现代世界,One Health 方法被认为是克服各种新发疾病(包括抗菌素耐药性 (AMR))的重要视角。AMR 感染的首要任务之一是由碳青霉烯类耐药肠杆菌科(CRE)引起的,这些细菌菌株对碳青霉烯类药物不敏感,碳青霉烯类药物是治疗革兰氏阴性菌临床感染的最后手段抗生素。尽管全球范围内不允许在动物中使用碳青霉烯类药物,但各种类型的 CRE 仍在动物中报告,包括产碳青霉烯酶肠杆菌科(CPE)。因此,由于 CPE 的传播和临床感染代表着共同的健康威胁,应从 One Health 方法的角度考虑提高对此问题认识的措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/155f/11611490/0fd5abee9e1a/jvs-25-e83-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/155f/11611490/0fd5abee9e1a/jvs-25-e83-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/155f/11611490/0fd5abee9e1a/jvs-25-e83-g001.jpg

相似文献

1
Awareness on the spread of carbapenem-resistant Enterobacterales in animals as One Health.动物中碳青霉烯类耐药肠杆菌科的传播意识作为一种健康。
J Vet Sci. 2024 Nov;25(6):e83. doi: 10.4142/jvs.24251.
2
Phenotypic and molecular characterization of multidrug-resistant Enterobacterales isolated from clinical samples in Palestine: a focus on extended-spectrum β-lactamase- and carbapenemase-producing isolates.巴勒斯坦临床样本中分离的多药耐药肠杆菌科的表型和分子特征:重点关注产超广谱β-内酰胺酶和碳青霉烯酶的分离株。
BMC Infect Dis. 2024 Aug 12;24(1):812. doi: 10.1186/s12879-024-09726-x.
3
Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.碳青霉烯类耐药肠杆菌科感染的治疗:最新进展和未来方向。
Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2053-2068. doi: 10.1007/s10096-021-04296-1. Epub 2021 Jun 24.
4
The influence of hospital antimicrobial use on carbapenem-non-susceptible Enterobacterales incidence rates according to their mechanism of resistance: a time-series analysis.根据耐药机制分析医院抗菌药物使用对碳青霉烯类药物不敏感肠杆菌科发生率的影响:时间序列分析。
J Hosp Infect. 2020 Aug;105(4):757-765. doi: 10.1016/j.jhin.2020.06.019. Epub 2020 Jun 18.
5
Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study.产碳青霉烯酶与非产碳青霉烯酶肠杆菌科细菌感染的危险因素:一项病例对照研究。
Clin Microbiol Infect. 2023 May;29(5):629-634. doi: 10.1016/j.cmi.2023.01.005. Epub 2023 Jan 12.
6
Multispecies emergence of dual carbapenemase-producing Enterobacterales recovered from invasive infections in Chile.从智利侵袭性感染中分离出的产双碳青霉烯酶肠杆菌科细菌的多物种出现情况。
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0120524. doi: 10.1128/aac.01205-24. Epub 2024 Dec 5.
7
Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.采用小鼠大腿感染模型,对美罗培南、头孢吡肟或氨曲南与新型β-内酰胺酶抑制剂那库巴坦联合用药,针对耐碳青霉烯类和/或产碳青霉烯酶的肺炎克雷伯菌和大肠埃希菌进行药效学评价。
Int J Antimicrob Agents. 2021 May;57(5):106330. doi: 10.1016/j.ijantimicag.2021.106330. Epub 2021 Mar 28.
8
Spatiotemporal and genomic analysis of carbapenem resistance elements in Enterobacterales from hospital inpatients and natural water ecosystems of an Irish city.爱尔兰某城市医院住院患者及自然水生态系统中肠杆菌科细菌碳青霉烯耐药元件的时空与基因组分析
Microbiol Spectr. 2025 Jan 7;13(1):e0090424. doi: 10.1128/spectrum.00904-24. Epub 2024 Nov 27.
9
Meropenem-Vaborbactam Activity against Carbapenem-Resistant Isolates Collected in U.S. Hospitals during 2016 to 2018.美罗培南-法硼巴坦对 2016 年至 2018 年期间美国医院分离的碳青霉烯类耐药菌株的活性。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01951-19.
10
Global spread of carbapenem-resistant Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy.全球碳青霉烯类耐药肠杆菌科的传播:流行病学特征、耐药机制、检测和治疗。
Microbiol Res. 2023 Jan;266:127249. doi: 10.1016/j.micres.2022.127249. Epub 2022 Nov 4.

本文引用的文献

1
Genomic molecular epidemiology of carbapenemase-producing Escherichia coli ST410 isolates by complete genome analysis.通过全基因组分析研究产碳青霉烯酶大肠埃希菌 ST410 分离株的基因组分子流行病学。
Vet Res. 2023 Sep 1;54(1):72. doi: 10.1186/s13567-023-01205-6.
2
Evidence for the transmission of antimicrobial resistant bacteria between humans and companion animals: A scoping review.人类与伴侣动物之间抗微生物耐药细菌传播的证据:一项范围综述。
One Health. 2023 Jun 26;17:100593. doi: 10.1016/j.onehlt.2023.100593. eCollection 2023 Dec.
3
An overview of carbapenem-resistant organisms from food-producing animals, seafood, aquaculture, companion animals, and wildlife.
来自食用动物、海鲜、水产养殖、伴侣动物和野生动物的耐碳青霉烯类微生物概述。
Front Vet Sci. 2023 Jun 15;10:1158588. doi: 10.3389/fvets.2023.1158588. eCollection 2023.
4
Molecular Epidemiology of Carbapenemases in from Humans, Animals, Food and the Environment.来自人类、动物、食物和环境的碳青霉烯酶分子流行病学
Antibiotics (Basel). 2020 Oct 13;9(10):693. doi: 10.3390/antibiotics9100693.
5
The dawn of phage therapy.噬菌体疗法的曙光。
Rev Med Virol. 2019 Jul;29(4):e2041. doi: 10.1002/rmv.2041. Epub 2019 May 3.
6
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria.噬菌体疗法:一种对抗抗生素耐药菌的新方法。
Cell Host Microbe. 2019 Feb 13;25(2):219-232. doi: 10.1016/j.chom.2019.01.014.
7
Hospitalized Pets as a Source of Carbapenem-Resistance.住院宠物作为耐碳青霉烯类药物的来源。
Front Microbiol. 2018 Dec 6;9:2872. doi: 10.3389/fmicb.2018.02872. eCollection 2018.
8
Antimicrobial resistance: A global emerging threat to public health systems.抗微生物药物耐药性:对公共卫生系统的全球新出现的威胁。
Crit Rev Food Sci Nutr. 2017 Sep 2;57(13):2857-2876. doi: 10.1080/10408398.2015.1077192.
9
The β-Lactams Strike Back: Ceftazidime-Avibactam.β-内酰胺类药物卷土重来:头孢他啶-阿维巴坦
Pharmacotherapy. 2015 Aug;35(8):755-70. doi: 10.1002/phar.1622.
10
Containment of carbapenem resistance rates of Klebsiella pneumoniae and Acinetobacter baumannii in a Greek hospital with a concomitant increase in colistin, gentamicin and tigecycline resistance.希腊一家医院中肺炎克雷伯菌和鲍曼不动杆菌碳青霉烯类耐药率得到控制,同时黏菌素、庆大霉素和替加环素耐药率上升。
New Microbiol. 2015 Jul;38(3):417-21. Epub 2015 Jul 6.